摘要
目的:探讨表皮生长因子受体酪氨酸激酶抑制剂吉非替尼在非小细胞肺癌治疗中的疗效分离现象的特点及对策。方法:分析北京军区总医院吉非替尼在非小细胞肺癌治疗中的疗效分离现象。结果:疗效分离现象可见于接受吉非替尼治疗的非小细胞肺癌骨和或脑转移患者,1例原发病灶疾病控制而骨转移病灶进展患者继续吉非替尼治疗临床获益。结论:在接受吉非替尼治疗的非小细胞肺癌患者中疗效分离倾向为常见现象,目前肿瘤治疗疗效评价标准及治疗策略可能不完全适于生物靶向治疗药物的评价,吉非替尼在非小细胞肺癌治疗中的疗效分离现象的分子机制及治疗策略值得进一步研究,并在此基础上建立适合分子靶向药物的疗效评价标准及治疗原则。
Objective： To investigate the characteristics and strategy of the therapeutic divergence phenomenon of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase （EGFR-TKI） , in the treatment of nonsmall cell lung cancer （ NSCLC）. Methods： The authors analyzed the therapeutic divergence phenomenon in 4 patiens with NSCLC during treatment with gefitinib at Bejing Military Area General Hospital between 2006 and 2008. Results： The therapeutic divergence phenomenon occurred in patients with NSCLC, who were complicated with bone and brain metastases and treated with gefitinib. In one of the four patients, NSCLC was controlled, but the disease recurred in the bone and gefitinib therapy continued, and the clinical benefit continued. Conclusion： The therapeutic divergence phenomenon is common in the patients with NSCLC treated with gefitinib. The available evaluation criterion for oncotheropeutic effect may be not completely suitable to biologically targeted therapy. The intrinsic mechanism of this phenomenon needs further research for the formulate evaluation criterion and therapeutic strategy suitable for the biologically targeted therapy.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第14期1320-1323,1327,共5页
Chinese Journal of New Drugs
关键词
非小细胞肺癌
酪氨酸激酶抑制剂
疗效分离
吉非替尼
靶向治疗
non-small cell lung cancer
tyrosine kinase inhibitor
therapeutic divergence phenomenon
gefitinib
targeted therapy
